VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

Leiden, The Netherlands, 19 July 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral presentation at the ISTH (International Society on Thrombosis and Haemostasis) Virtual Congress on Tuesday, 20 July, 2021 at 11.00-12.00 EDT.

The effective reversal of anticoagulation is important to ensure the safety of treatment with direct oral factor FXa-inhibiting anticoagulants (DOACs). VarmX is developing VMX-C001, a modified recombinant blood factor X that is insensitive to FXa-DOACs, as a reversal agent for the treatment of severe spontaneous bleeding in patients taking DOACs.

At the ISTH Congress, Director of Research Daniël Verhoef will present new preclinical data demonstrating that VMX-C001 is an effective DOAC reversal agent and displays no thrombogenic potential when compared to products that are currently being used in the clinic to stop DOAC-associated bleeding. The abstract, which was selected by the conference organisers for oral presentation, is available here.

Pieter Reitsma, Founder and CSO of VarmX, commented: “We are happy and grateful that the ISTH Congress organisers have recognised the impact and importance of this preclinical data, which differentiates VMX-C001 from other products. The work is the product of our ongoing collaboration with the Division of Thrombosis and Hemostasis at Leiden University Medical Center, and is helping to pave the path to the clinical development of our lead programme.”

Event: ISTH 2021 Virtual Congress

Title: VMX-C001 is an effective FXa-DOAC reversal agent and displays no thrombogenic potential in comparison to andexanet alfa and 4PCC

Session: OC 46 Modulation of Hemostasis-Clinical Assessment

Date: 20 July 2021

Time: 11.00-12.00 EDT

Location: Virtual Meeting Room 7


For further information, please contact:

VarmX B.V.

Dr. Jan Öhrström, CEO

Instinctif Partners (media enquiries)

Melanie Toyne-Sewell / Katie Duffell

Tel: +44 20 7457 2020


Notes to Editors

About VarmX 

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X based on the venom of the Australian brown snake, Pseudonaja textilis. The compound is being developed for the treatment of severe spontaneous bleeding in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. In July 2020, the Company raised €32m in a series B financing, supported by a strong syndicate of investors including Ysios Capital, INKEF Capital, Lundbeckfonden Ventures, LSP, BioGeneration Ventures and the regional economic development fund, InnovationQuarter. For more information:

This website uses functional and analytical cookies. Accept Deny